Vertex Pharmaceuticals Incorporated (VRTX) Stock Price Today
Aura AI Summary
Key Stats
- $112.12BMARKET_CAP
- -VOLUME
- HealthSECTOR
- $528.04FIFTY_TWO_WEEK_HIGH
- $366.54FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $106.86BENTERPRISE_VALUE
- -DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $366.54 and a high of $528.04, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Most Recent News
Virtual machine market to reach $53.52B by 2035 driven by AI, cloud, and hybrid IT growth
The global virtual machine market, valued at $13.7 billion in 2025, is projected to grow at a CAGR of 14.6% to reach $53.52 billion by 2035. Growth is fueled by rising adoption of cloud computing, hybrid IT infrastructure, AI workloads, and enterpris...
Automotive composites market to hit $71.21B by 2034, driven by EV demand and lightweight materials.
The global automotive composites market is projected to grow from $29.13 billion in 2025 to $71.21 billion by 2034, at a CAGR of 10.4%. Growth is fueled by increasing demand for lightweight, fuel-efficient vehicles, especially electric and premium ca...
Sweden's flu diagnostics and treatment market to grow 4.1% CAGR, driven by rapid molecular tests and antiviral therapies.
The Sweden flu diagnostic and treatment market is projected to grow from USD 172.1 million in 2026 to USD 210.3 million by 2031, at a 4.1% CAGR. Growth is driven by high influenza burden among seniors, increased demand for rapid molecular diagnostics...